Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + obinutuzumab versus chlorambucil + obinutuzumab in previously untreated CLL/SLL
2014-002069-31Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- Sep 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Ibrutinib + obinutuzumab with Chlorambucil + obinutuzumab (2 arms). Primary endpoint: Progression-free survival. Started Sep 2014; status: completed.
02
Drugs
ibrutinibobinutuzumabchlorambucil
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2014-002069-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002069-31.